Naltrexone

BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD

Retrieved on: 
Wednesday, February 28, 2024

Clinical studies have supported the use of naltrexone in the treatment of MUD, as well as the combination of naltrexone with bupropion to significantly reduce the use of methamphetamines.

Key Points: 
  • Clinical studies have supported the use of naltrexone in the treatment of MUD, as well as the combination of naltrexone with bupropion to significantly reduce the use of methamphetamines.
  • MUD represents a significant public health concern, with devastating consequences for individuals, families, and communities across the country.
  • Despite the growing prevalence of MUD, effective treatment options remain limited, underscoring the urgent need for innovative approaches to address this complex and challenging condition.
  • Currently, there are no approved medications for MUD, and populations at risk of methamphetamine-involved overdose deaths are diversifying.

BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors

Retrieved on: 
Thursday, February 8, 2024

ANAHEIM, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc., has appointed Kate Beebe DeVarney, Ph.D. to its Board of Directors.

Key Points: 
  • ANAHEIM, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc., has appointed Kate Beebe DeVarney, Ph.D. to its Board of Directors.
  • Dr. DeVarney is the President, Chief Operating Officer, and a Director of Titan Pharmaceuticals, Inc.  She was previously Titan’s Chief Scientific Officer and has been with the company since 2007.
  • Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., commented, “We are honored and excited to welcome Dr. DeVarney to the BioCorRx Pharmaceuticals board.
  • I look forward to working closely with the management team to bring BICX104 to market.”

Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 26, Status: Authorised

Retrieved on: 
Tuesday, January 9, 2024

Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 26, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Relistor, methylnaltrexone bromide, Date of authorisation: 01/07/2008, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Relistor, methylnaltrexone bromide, Date of authorisation: 01/07/2008, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Relistor, methylnaltrexone bromide, Date of authorisation: 01/07/2008, Revision: 19, Status: Authorised

BioCorRx Reports Business Update for the Third Quarter of 2023

Retrieved on: 
Tuesday, November 14, 2023

ANAHEIM, CA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended September 30, 2023, and reported on recent corporate developments.

Key Points: 
  • ANAHEIM, CA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended September 30, 2023, and reported on recent corporate developments.
  • Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., commented, “We believe that the high and sustained concentrations of naltrexone released by BICX104 hold the potential to significantly curtail opioid overdose deaths.
  • We reduced our total operating expenses by over $600,000 for the nine months ended September 30, 2023 compared to the same period last year.
  • Overall, we remain encouraged by the outlook for the business and look forward to providing additional operational and regulatory updates soon,” concluded Ms. Felix.

Hims & Hers Launches Holistic Weight Loss Program to Break the Endless Cycle of Weight Gain and Loss

Retrieved on: 
Monday, December 4, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231204073836/en/
    Weight Loss by Hims & Hers (Graphic: Business Wire)
    The science-backed Weight Loss by Hims & Hers program is developed with the expert insight of Dr. Primack and a team of clinical experts in obesity medicine, psychology and nutrition.
  • The program offers a well-rounded and more affordable approach to reducing weight by addressing the underlying factors that affect people’s weight – Nutrition, Behavior, Movement and Medical Treatment.
  • Weight Loss by Hims & Hers aims to address these issues by taking on the physical and psychological factors that contribute to weight gain and loss.
  • For more information on Hims & Hers’ weight loss program, please visit https://www.forhers.com/weight-loss and https://www.hims.com/c/wm/introduction .

Opioid Use Disorder Market Insights, Epidemiology and Forecasts, 2019-2032: Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Friday, October 27, 2023

The "Opioid Use Disorder (OUD)" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Key Points: 
  • The "Opioid Use Disorder (OUD)" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
  • The Opioid Use Disorder (OUD) market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Opioid Use Disorder (OUD) market size from 2019 to 2032.
  • Opioid Use Disorder (OUD) Treatment FDA-approved drugs such as Buprenorphine, methadone, and naltrexone have proven effective in treating Opioid Use Disorder, decreasing overdose rates.
  • Which type of Opioid Use Disorder (OUD), as per severity, is the largest contributor to the Opioid Use Disorder (OUD) patient pool?

Cessation Therapeutics Awarded $14.8 Million Grant from the National Institute of Drug Abuse to Develop Novel Formulation of Anti-Fentanyl Monoclonal Antibody

Retrieved on: 
Wednesday, October 18, 2023

The new grant (UG3DA058544) is part of a multi-year award expected to total $14.8 million given to Cessation and McLean Hospital, a member of Mass General Brigham.

Key Points: 
  • The new grant (UG3DA058544) is part of a multi-year award expected to total $14.8 million given to Cessation and McLean Hospital, a member of Mass General Brigham.
  • Through different delivery methods, the platform can be optimized to potentially protect against overdose, reverse overdose, and treat fentanyl-related opioid use disorder (OUD).
  • “We are grateful to NIDA for their continued support of Cessation’s anti-fentanyl development programs,” said Andy Barrett, PhD, Chief Scientific Officer at Cessation Therapeutics.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Adial Pharmaceuticals to Host a Virtual Key Opinion Leader Webinar to Discuss the Unmet Need in Alcohol Use Disorder

Retrieved on: 
Thursday, September 28, 2023

CHARLOTTESVILLE, Va., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that on October 4, 2023, at 2:15 p.m. Eastern Time, it will be hosting a LinkedIn Live Key Opinion Leader (KOL) webinar to discuss AUD, the current treatment landscape, and the need for non-abstinence-based therapeutics.

Key Points: 
  • The webinar will be a panel discussion between leading experts in the addiction field - Joseph Volpicelli, M.D., Ph.D, and Jonathan Hunt-Glassman, MBA - and moderated by Brookline Capital Senior Analyst and Director of Research, Kemp Dolliver.
  • Dr. Volpicelli is the Executive Director and founder of the Volpicelli Center for Addiction.
  • Dr. Volpicelli is a featured author of over 100 academic publications and two of his own books on addiction treatment.
  • He has over 17 years of experience in the healthcare industry, including UnitedHealth and Humana.

Aphios Awarded an NIH Grant For a Combination Therapeutic for Chronic Opioid Use Disorder Relapse

Retrieved on: 
Wednesday, September 6, 2023

Aphios announced today that it was awarded an NIH grant to develop a combination therapeutic for chronic opioid use disorder relapse.

Key Points: 
  • Aphios announced today that it was awarded an NIH grant to develop a combination therapeutic for chronic opioid use disorder relapse.
  • Aphios was awarded a Phase I Small Business Innovation Research (SBIR) grant to develop a sustained release combination therapeutic for chronic opioid use disorder relapse that includes cannabidiol (CBD) in biodegradable polymer nanospheres.
  • Unlike current treatments, cannabidiol (CBD), a bioactive ingredient of marijuana, is not an opioid and is non-psychoactive.
  • According to Dr. Trevor P. Castor, Aphios’ President and CEO, “CBD encapsulated in nanoparticles will improve therapeutic efficacy for opioid use disorder relapse while reducing side-effects, and increasing adherence and accessibility.